<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00426868</url>
  </required_header>
  <id_info>
    <org_study_id>PRECISE-01</org_study_id>
    <nct_id>NCT00426868</nct_id>
  </id_info>
  <brief_title>A Randomized Clinical Trial of Adipose-derived Stem Cells in Treatment of Non Revascularizable Ischemic Myocardium</brief_title>
  <official_title>A Randomized Clinical Trial of adiPose-deRived stEm &amp; Regenerative Cells In the Treatment of Patients With Non revaScularizable ischEmic Myocardium - The PRECISE Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cytori Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cytori Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to establish safety and feasibility of utilizing Adipose Derived
      Stem &amp; Regenerative Cells (ADRCs) in patients who have areas of myocardium that are not
      revascularizable and have demonstrated reversible ischemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects who have coronary artery disease that cannot be revascularized and demonstrate
      reversible ischemia in the area supplied by the non-revascularizable vessel(s) will be
      evaluated for eligibility in this study. Eligible subjects will undergo standard
      pre-operative testing after admission to the hospital, and then will undergo liposuction
      under anesthesia, after which ADRCs will be isolated from the lipoaspirate. According to
      randomization subjects will receive either ADRCs or placebo.

      The outcomes of this trial will be based on assessment of primary and secondary endpoints at
      6 months post index procedure. Long Term Follow-up will be conducted at 12, 18, 24 and 36
      months after the procedure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety - Determined by Major Adverse Cardiac and Cerebral Events (MACCE)</measure>
    <time_frame>Up to 36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feasibility - Assessment of cardiac function using a variety of functional and imaging studies including MRI, SPECT and Echocardiography</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Ischemic Heart Disease</condition>
  <condition>Coronary Arteriosclerosis</condition>
  <condition>Cardiovascular Disease</condition>
  <condition>Coronary Disease</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Direct injection of ADRCs into the Left Ventricle</intervention_name>
    <description>Dose escalation</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Direct injection of placebo into the Left Ventricle</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Able to provide written informed consent

          -  Males or females 20 to 75 years of age, inclusive

          -  Coronary artery disease not amenable to any type of revascularization procedure
             (percutaneous or surgical) in the target area

          -  Hemodynamic stability

          -  Ability to undergo liposuction

          -  Ability to walk on a treadmill

          -  Negative urine pregnancy test (females only).

        Key Exclusion Criteria:

          -  Unstable angina

          -  Serum creatinine &gt;2.5 mg/dL

          -  Planned or scheduled staged treatment of CAD or other interventional or surgical
             procedures

          -  Cardiogenic shock

          -  History of resuscitated sudden cardiac death; or symptomatic or sustained ventricular
             fibrillation or ventricular tachycardia.

          -  Vascular anatomy that precludes cardiac catheterization

          -  Peripheral artery disease that precludes insertion of an 8 Fr sheath

          -  Severe valvular disease

          -  Pregnant or nursing females

          -  Known and relevant allergies or sensitivities

          -  Life expectancy &lt;1 year

          -  Participation in any other clinical research study that has not reached its primary
             endpoint or otherwise would interfere with the subject's participation in this study

          -  Any concurrent disease or condition that, in the opinion of the investigator, would
             make the subject unsuitable for participation in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander M Milstein, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cytori Therapeutics, Inc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francisco J Fernández-Avilés, MD, PhD, FACC, FESC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital G.U. Gregorio Marañón</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emerson C Perin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Heart Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rigshospitalet University Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus University Medical Centrum, Thorax Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utrecht Medical Center</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Netherlands</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2007</study_first_submitted>
  <study_first_submitted_qc>January 24, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2007</study_first_posted>
  <last_update_submitted>August 27, 2013</last_update_submitted>
  <last_update_submitted_qc>August 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ADRC</keyword>
  <keyword>Stem Cells</keyword>
  <keyword>chronic ischemia</keyword>
  <keyword>heart disease</keyword>
  <keyword>coronary artery disease</keyword>
  <keyword>inducible reversible ischemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Arteriosclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

